10-Q: Natural Alternatives International Reports Q1 2025 Results with Net Loss Amidst Sales Shift and Increased Costs

Natural Alternatives International reported a net loss for the first quarter of fiscal year 2025, impacted by decreased private-label contract manufacturing sales and increased operating costs, despite growth in patent and trademark licensing revenue.

Summary

• Natural Alternatives International (NAI) reported a net loss of $1.982 million for the quarter ended September 30, 2024, compared to a net loss of $695,000 for the same period last year.
• Net sales decreased by 2% to $33.15 million, with a 5% decrease in private-label contract manufacturing sales offset by a 42% increase in patent and trademark licensing revenue.
• The company experienced a decrease in gross profit margin from 9.2% to 6.8%, primarily due to an unfavorable change in product sales mix and increased manufacturing costs.
• Selling, general, and administrative expenses increased by 11% to $4.095 million, driven by higher compensation, benefits, and legal fees.
• Other expenses increased by 70% to $577,000 due to unfavorable foreign currency volatility and increased interest expense.
• NAI was not in compliance with certain financial covenants of its credit facility as of September 30, 2024, and anticipates continued non-compliance in the next two quarters.
• The company is currently negotiating a potential revised credit facility or waiver with its lender, Wells Fargo.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the company's net loss, decreased gross profit margin, non-compliance with financial covenants, and the need to renegotiate its credit facility. While there are some positive developments, the overall financial performance is concerning.

Positives

• Patent and trademark licensing revenue increased by 42% year-over-year, reaching $2.52 million.
• The company launched a new product, TriBsyn, which is a carnosine booster with patent-pending technology.
• NAI is actively working on additional innovations for its CarnoSyn product line.
• The company is seeking to diversify its sales base by developing relationships with additional private-label contract manufacturing customers.

Negatives

• Net sales decreased by 2% compared to the same quarter last year.
• Private-label contract manufacturing sales decreased by 5% due to reduced orders from a major customer.
• The company experienced a net loss of $1.982 million, a significant increase from the $695,000 loss in the same quarter last year.
• Gross profit margin decreased to 6.8% from 9.2% due to increased manufacturing costs and a change in sales mix.
• NAI is not in compliance with certain financial covenants of its credit facility.
• The company anticipates a net loss in the first half of fiscal 2025 and an overall net loss for the fiscal year.

Risks

• The company is heavily reliant on a few major customers, with one customer accounting for 37% of total net sales in the current quarter.
• NAI is dependent on a limited number of raw material suppliers, and the loss of any of these suppliers could have a material adverse impact.
• The company is not in compliance with certain financial covenants of its credit facility and is negotiating a potential revision or waiver.
• The company anticipates continued non-compliance with financial covenants in the next two quarters.
• Geopolitical instability, including conflicts in Ukraine and the Middle East, may adversely affect business operations.
• The company faces risks related to foreign currency exchange rate fluctuations.

Future Outlook

The company anticipates a net loss in the first half of fiscal 2025, net income in the second half of fiscal 2025, and an overall net loss for the fiscal 2025 year. NAI plans to continue its focus on leveraging its facilities, expanding the commercialization of its beta-alanine patent estate, and improving operational efficiencies.

Management Comments

• A cornerstone of our business strategy is to achieve long-term growth and profitability and to diversify our sales base.
• We have sought and expect to continue to seek to diversify our sales by developing relationships with additional, quality-oriented, private-label contract manufacturing customers, and commercializing our patent estate.
• We believe SR CarnoSyn may provide a unique opportunity within the growing Wellness and Healthy Aging markets.
• We believe TriBsyn may allow us to better penetrate the Wellness and Healthy Aging channel.
• We believe our efforts to refine our formulations and product offerings will be positively received and result in significant opportunity for increased sales of our patented products.
• Although our overall sales forecast for fiscal 2025 includes a significant increase in sales as compared to fiscal 2024, we now anticipate we will experience a net loss in the first half of fiscal 2025, net income in the second half of fiscal 2025, and an overall net loss for the fiscal 2025 year.

Industry Context

The company operates in the nutritional supplement and contract manufacturing industry, which is subject to fluctuations in customer demand, raw material costs, and regulatory requirements. The launch of TriBsyn and continued focus on the Wellness and Healthy Aging market reflects a broader industry trend towards innovative and specialized products.

Comparison to Industry Standards

• The decrease in gross profit margin to 6.8% is below the industry average for contract manufacturers, which typically ranges from 10% to 20%.
• The company's reliance on a few major customers is a common risk in the contract manufacturing sector, but NAI's concentration is higher than some of its peers.
• The increase in patent and trademark licensing revenue is a positive sign, as companies with strong intellectual property portfolios often command higher margins.
• Compared to companies like Nutra Manufacturing and Capstone Nutrition, NAI's financial performance in this quarter is weaker, particularly in terms of profitability.
• The company's non-compliance with financial covenants is a concern, as it indicates potential financial instability compared to industry benchmarks.

Legal Proceedings

• The company is involved in various investigations, claims, and legal proceedings that arise in the ordinary course of business.
• As of November 13, 2024, neither NAI nor NAIE were a party to any material pending legal proceeding.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and decreased profitability.
• Employees may be affected by potential cost-cutting measures.
• Customers may experience changes in product availability or pricing due to supply chain and financial challenges.
• Suppliers may face uncertainty due to the company's financial situation.
• Creditors are at risk due to the company's non-compliance with financial covenants.

Next Steps

• The company will continue sales and marketing activities to promote its CarnoSyn, SR CarnoSyn, and TriBsyn products.
• NAI will continue to negotiate a potential revised credit facility or waiver with Wells Fargo.
• The company will focus on improving operational efficiencies and managing costs to improve profitability.
• NAI will continue to invest in research and development for the expansion of its CarnoSyn product offerings.

Key Dates

Keywords

contract manufacturing, beta-alanine, CarnoSyn, SR CarnoSyn, TriBsyn, nutritional supplements, patent licensing, financial results, net loss, revenue, gross profit, credit facility, financial covenants